What Is the Life Expectancy After a Heart Stent?

Most people who receive a coronary stent live for many years afterward, and the stent itself does not impose a fixed expiration date. Survival depends far more on the underlying heart disease, the reason the stent was placed, and the patient’s overall health than on the metal scaffold sitting inside the artery. Large registry studies have tracked patients for 10 to 15 years after stenting, and the numbers vary enormously depending on individual factors like age, heart function, diabetes, and kidney health. Understanding those variables gives a much more useful picture than any single life-expectancy figure could.

What the Survival Numbers Actually Look Like

A Brazilian registry that followed over 90,000 patients who received stents through the public healthcare system found that roughly 97 percent survived the first 30 days, about 93 percent were alive at one year, and around 56 to 58 percent were still alive at 15 years.¹ Those 15-year figures reflect an era that included older stent designs and a patient population spanning all ages and conditions, so they are not a prediction for any individual. A European analysis of two randomized trials reported 10-year all-cause death rates of about 23 percent in men and 29 percent in women, with stented patients dying at roughly 1.6 to 2.1 times the rate of the general population matched for age and sex.² That gap tells you something important: having coronary artery disease serious enough to need a stent means your risk profile is higher than someone the same age without heart disease. The stent treats a narrowed artery, but it does not erase the disease that caused the narrowing.

Why the Reason for Your Stent Matters So Much

The single biggest divider in post-stent outcomes is whether the procedure was done during a heart attack or for stable chest pain. Emergency stenting during a heart attack carries a higher short-term risk because the heart muscle may already be damaged, blood clots are actively forming, and some patients arrive in cardiogenic shock. A review of in-hospital deaths after stenting found that the vast majority occurred in patients who came in during a heart attack, and most of those deaths were related to the patient’s underlying condition rather than a complication of the procedure itself.³

For patients with stable coronary artery disease, meaning chest pain or narrowed arteries found on testing without an acute event, the picture is different. A landmark trial comparing stenting plus optimal medication against medication alone in stable patients found no difference in death or heart attack rates after about four and a half years, although the stent group reported better quality of life.⁴ That result reshaped thinking about when stents actually extend life versus when they mainly relieve symptoms. In stable disease, the stent is not necessarily buying you extra years; the medications and lifestyle changes are doing most of the heavy lifting on survival.

How Age Shapes the Outlook

Older patients face higher absolute mortality after stenting, which is unsurprising because older people face higher mortality from everything. The more useful question is whether stenting changes their trajectory relative to their peers. One study of patients aged 80 and older who received drug-eluting stents found a 12-month mortality rate of about 9 percent, compared with 3 percent in younger patients. But after adjusting for age and sex, the octogenarians’ life expectancy was statistically similar to that of the general population the same age.⁵ In other words, the stent procedure did not add extra risk on top of being 80; it brought these patients roughly back to baseline. That is reassuring for older adults weighing whether the procedure is worth it.

The European analysis mentioned earlier found that both women and men who had stents placed carried a higher mortality risk than the general population between roughly their mid-50s and early 80s. Below and above those age windows, the excess risk was less pronounced.² The practical takeaway is that middle-aged stent recipients have the most room to improve their outlook through aggressive risk-factor management, because they are the group with the biggest gap between their actual survival and what it could be.

Heart Function Is a Powerful Predictor

How well your heart pumps blood, measured as left ventricular ejection fraction, turns out to be one of the strongest predictors of how long you live after stenting. A normal ejection fraction is generally 50 percent or higher. In a study of patients undergoing stenting during a heart attack, three-year mortality was about 3 to 4 percent in those with normal pump function but jumped to about 17 percent in those with an ejection fraction below 40 percent. Among the sickest group, those with an ejection fraction under 30 percent, three-year mortality reached nearly 30 percent.⁶

The encouraging news is that when stenting restores blood flow to damaged heart muscle, ejection fraction can improve, and that improvement translates into better survival. A recent study of patients who had follow-up heart imaging after their procedure found that for every five percentage points their ejection fraction rose, the risk of long-term death dropped measurably. This benefit was strongest in patients who started with reduced pump function, where the heart had the most room to recover.⁷ In patients who already had a normal ejection fraction before stenting, the procedure did not meaningfully change pump function or long-term mortality. The message here is that stenting can genuinely extend life when it rescues heart muscle that is struggling from poor blood supply, but does less for survival when the heart was pumping fine all along.

Data from the SYNTAX trial showed similar patterns over a longer follow-up. At 10 years, patients with reduced ejection fraction had a mortality rate of about 44 percent, compared with roughly 23 percent in those with preserved pump function.⁸

Diabetes, Kidney Disease, and Other Conditions

Diabetes is one of the most consistent predictors of worse outcomes after stenting. While modern drug-eluting stents have largely solved the extra risk of the artery re-narrowing that diabetic patients used to face, the risks of dying and of blood clot complications remain higher for people with diabetes than for those without.⁹ A large U.S. registry study of older patients found that insulin-treated diabetics had roughly double the adjusted risk of death compared with non-diabetic patients, while non-insulin-treated diabetics had about a third higher risk.¹⁰ These numbers underline why cardiologists treat glucose control as a core part of post-stent care.

Kidney disease is equally important. In patients with impaired kidney function who received stents, the mortality rate was roughly triple that of patients with normal kidneys over a similar follow-up period.¹¹ A separate study looking at eight-year survival found that patients on dialysis who received stents had an adjusted survival rate of about 41 percent, compared with roughly 80 percent in patients without kidney disease.¹² Kidney disease accelerates atherosclerosis, impairs the body’s ability to handle blood-thinning medications, and complicates nearly every aspect of cardiovascular care.

Modern Stents Compared with Older Designs

The stent you receive matters. Bare-metal stents, the original technology, had a significant problem with the artery re-narrowing inside the stent over the first year. Drug-eluting stents, which release medication to suppress that scar-tissue buildup, largely fixed that issue. A large network analysis comparing multiple stent types found that newer-generation everolimus-eluting stents had lower rates of death, stent clotting, and heart attacks than bare-metal stents and several older drug-eluting designs.¹³

The survival advantage of drug-eluting over bare-metal stents shows up most clearly in the first year. At one year, drug-eluting stents were associated with lower mortality and substantially fewer repeat procedures.¹⁴ However, a large randomized trial comparing current-generation drug-eluting stents against bare-metal stents at six years found no significant difference in the combined rate of death, heart attack, or stroke, though repeat procedures were still less common with drug-eluting stents.¹⁵ A German observational study confirmed that drug-eluting stent patients had about a 21 percent lower mortality risk than bare-metal stent patients even after adjusting for other differences.¹⁶ If you received a bare-metal stent years ago, that does not mean you are in danger, but the technology has genuinely improved outcomes for newer recipients.

Medications That Influence Long-Term Survival

A stent is only as good as the medication regimen that supports it. Two drug categories deserve special attention: blood thinners (specifically dual antiplatelet therapy) and statins.

After stenting, patients are placed on two antiplatelet drugs to prevent blood clots from forming inside the stent. How long to continue both drugs has been one of the most studied questions in cardiology. A large Veterans Affairs study found that stopping dual antiplatelet therapy before about nine months was associated with a higher risk of death, heart attacks, and cardiac death, but continuing it beyond nine months did not add further benefit and was actually linked to lower risks of both clotting and bleeding events.¹⁷ A systematic review confirmed that extending dual therapy beyond 12 months increased the risk of major bleeding and non-cardiac death without a clear reduction in heart attacks, particularly with newer-generation stents.¹⁸ For diabetic patients specifically, maintaining antiplatelet therapy for more than nine months was associated with dramatically lower death rates compared with shorter courses.¹⁹

Statins are the other pillar. In a study of over 7,000 stent patients, those discharged on a statin had roughly half the risk of dying within a year compared with those who were not.²⁰ That survival benefit appeared as early as 30 days after the procedure and persisted at six months.²¹ In patients stented during a heart attack, starting a statin early was independently associated with better outcomes over three years.²² Statins do more than just lower cholesterol; they stabilize the fatty plaques throughout the arteries, reduce inflammation, and improve the function of the artery lining. For stent patients, they are not optional.

Cardiac Rehabilitation and Exercise

Cardiac rehab, a supervised program of exercise, education, and risk-factor coaching, is one of the most underused tools in post-stent care. Among older coronary patients, those who participated in cardiac rehab had roughly a 21 to 34 percent lower five-year mortality rate than those who did not, depending on the analytical method used. Patients who completed 25 or more sessions fared even better than those who attended fewer.²³ A separate study found that cardiac rehab independently predicted lower all-cause mortality and fewer hospital readmissions over long-term follow-up.²⁴

Exercise-based rehab also appears to help the stent itself stay open. In one trial, patients who went through a structured cardiac rehab program had less artery re-narrowing inside their stents at nine months compared with patients who did not exercise.²⁵ Despite the strong evidence, fewer than half of eligible patients in most countries actually enroll in cardiac rehab. If you have had a stent placed and have not been referred to a program, it is worth asking about.

Does It Matter If Every Blockage Is Treated?

Many patients who need stenting have disease in more than one artery. Whether all significant blockages are treated during the stent procedure, known as complete revascularization, has a measurable effect on outcomes. A meta-analysis found that patients who had all their significant blockages addressed had about a 31 percent lower odds of dying and about a 36 percent lower odds of having a heart attack compared with patients who had incomplete treatment.²⁶ Incomplete revascularization was also associated with higher 18-month mortality in a separate analysis of drug-eluting stent patients.²⁷ Sometimes complete treatment is not technically feasible or the risk of a longer procedure outweighs the benefit, but when it is possible, getting all the blockages treated in one go appears to pay off.

When Bypass Surgery Offers a Longer Life

For patients with disease in multiple arteries or with complex anatomy, coronary artery bypass grafting sometimes produces better long-term survival than stenting. A five-year randomized trial comparing stents with bypass surgery in patients with multivessel disease found essentially identical death rates, about 8 percent in each group. However, the stent group needed far more repeat procedures, with about 30 percent undergoing additional intervention compared with roughly 9 percent in the surgical group.²⁸ A ten-year trial of patients with stable multivessel disease showed no significant survival difference among medical therapy alone, stenting, or surgery, with survival rates of about 63, 69, and 66 percent respectively.²⁹

The exception is diabetic patients with multivessel disease. An economic and outcomes analysis from the FREEDOM trial, which specifically enrolled diabetics, projected substantial gains in both life expectancy and quality of life with bypass surgery compared with stenting.³⁰ Similarly, the SYNTAX trial suggested that patients with reduced heart function tended to fare better with bypass surgery than stenting over 10 years, although the difference did not quite reach statistical significance.⁸ For most other patients, the choice between stent and surgery comes down to anatomy, preferences, and how many arteries are involved rather than a clear survival advantage either way.

What Stent Patients Actually Die From Years Later

Here is a finding that surprises many people: among stent patients who die years after their procedure, the majority do not die of heart-related causes. A study tracking trends in death after stenting across three eras found a 50 percent decline in cardiac deaths at five years over time, driven largely by fewer sudden deaths and heart attacks. Meanwhile, non-cardiac deaths rose, mostly from cancer and other chronic diseases. In the most recent era studied, only about 37 percent of deaths after stenting were cardiac.³¹ This shift reflects both that heart treatments have gotten better and that the typical stent patient is older and carries multiple health conditions. It means that focusing exclusively on cardiac risk misses the bigger picture for long-term survival. Cancer screening, managing lung disease, and addressing other age-related conditions are all part of living longer after a stent.

Stent thrombosis, the dreaded complication where a blood clot forms inside the stent, is rare but deadly when it occurs. In pooled data from clinical trials, cardiac death within four years occurred in about 32 percent of patients who experienced stent thrombosis, compared with roughly 2.5 percent of those who did not. Early stent thrombosis, occurring in the first month, was especially lethal.³² Fortunately, stent thrombosis rates have fallen below 1 percent with newer-generation devices and appropriate blood-thinner use.¹⁵

Sex Differences After Stenting

Women who receive stents tend to have higher raw mortality rates than men, but that gap is mostly explained by the fact that women undergoing stenting are typically older and carry more risk factors at the time of their procedure. After adjusting for those differences, a large pooled analysis of nearly 10,000 patients found no significant difference between women and men in the rate of cardiovascular death over 10 years. Women did have a higher risk of heart attack in the first 30 days after stenting, but that early excess risk faded and was comparable to men’s risk afterward. Women were actually less likely to need repeat procedures on their stented arteries over the long term.³³

Depression, Anxiety, and the Overlooked Survival Factor

Mental health is not something most people think about when asking how long they will live after a stent, but the data is hard to ignore. In a study following stent patients for 10 years, those with depression at the time of their procedure had a 37 percent cumulative mortality rate compared with 20 percent in non-depressed patients. After adjusting for other risk factors, depression was still associated with roughly a 77 percent higher risk of dying. Anxiety, which looked benign in the unadjusted analysis, also emerged as a predictor of death once other factors were accounted for, with about a 50 percent higher risk.³⁴ The mechanisms likely include worse adherence to medications, less physical activity, higher stress-hormone levels, and more inflammation. Screening for and treating depression and anxiety after a heart procedure is not a soft recommendation; it has hard implications for survival.